InflaRx (NASDAQ:IFRX) Given New $6.00 Price Target at Cantor Fitzgerald

InflaRx (NASDAQ:IFRX) had its price objective raised by Cantor Fitzgerald from $4.00 to $6.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 248.84% from the stock’s previous close.

IFRX has been the subject of several other research reports. Zacks Research raised shares of InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 price target on the stock. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.33.

InflaRx Trading Down 2.8%

Shares of NASDAQ:IFRX opened at $1.72 on Friday. InflaRx has a twelve month low of $0.74 and a twelve month high of $2.95. The company has a market cap of $124.34 million, a PE ratio of -2.42 and a beta of 2.48. The company’s 50 day moving average is $1.91 and its 200 day moving average is $1.53.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Equities research analysts predict that InflaRx will post -0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its position in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the period. HRT Financial LP acquired a new position in InflaRx in the 4th quarter worth about $47,000. Concurrent Investment Advisors LLC boosted its position in InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC purchased a new position in InflaRx during the fourth quarter worth approximately $61,000. Finally, Quadrature Capital Ltd acquired a new stake in InflaRx in the fourth quarter valued at approximately $104,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.